These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 17552029)

  • 21. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology of hepatocellular carcinoma in Japan.
    Umemura T; Ichijo T; Yoshizawa K; Tanaka E; Kiyosawa K
    J Gastroenterol; 2009; 44 Suppl 19():102-7. PubMed ID: 19148802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatocellular Carcinoma Occurrence and Recurrence after Antiviral Treatment in HCV-Related Cirrhosis. Are Outcomes Different after Direct Antiviral Agents? A Review.
    Spârchez Z; Mocan T
    J Gastrointestin Liver Dis; 2017 Dec; 26(4):403-410. PubMed ID: 29253056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
    Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
    World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
    Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
    Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does chemotherapy prevent HCV-related hepatocellular carcinoma? Cons.
    Craxì A; Cammà C
    Dig Liver Dis; 2010 Jul; 42 Suppl 3():S287-92. PubMed ID: 20547316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis.
    Cheinquer N; Cheinquer H; Wolff FH; Coelho-Borges S
    Braz J Infect Dis; 2010; 14(5):457-61. PubMed ID: 21221473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does antiviral therapy prevent hepatocellular carcinoma?
    Kwon H; Lok AS
    Antivir Ther; 2011; 16(6):787-95. PubMed ID: 21900710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients.
    Ishikawa T
    World J Gastroenterol; 2008 Oct; 14(40):6140-4. PubMed ID: 18985803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
    Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
    Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
    Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus.
    Hung CH; Lee CM; Wang JH; Tung HD; Chen CH; Lu SN
    J Gastroenterol Hepatol; 2005 Oct; 20(10):1553-9. PubMed ID: 16174073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?
    Wang CC; Kao JH
    Expert Opin Pharmacother; 2016; 17(7):911-9. PubMed ID: 26831361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
    Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans.
    El-Serag HB; Kramer J; Duan Z; Kanwal F
    Am J Gastroenterol; 2014 Sep; 109(9):1427-35. PubMed ID: 25070058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Managing hepatitis C in patients with the complications of cirrhosis.
    Mücke MM; Mücke VT; Lange CM; Zeuzem S
    Liver Int; 2018 Feb; 38 Suppl 1():14-20. PubMed ID: 29427491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Combined interferon, ribavirin treatment and the occurrence of hepatocellular carcinoma].
    Lengyel G; Fehér J
    Orv Hetil; 2010 Jul; 151(29):1177-81. PubMed ID: 20591786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis].
    Schott E; Bergk A; Berg T
    Z Gastroenterol; 2008 Jan; 46(1):69-80. PubMed ID: 18188819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Achieving sustained virological response: what's the impact on further hepatitis C virus-related disease?
    van der Meer AJ
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):559-66. PubMed ID: 25579804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.